ColonBroom emphasizes a plant-based, non-GMO blend built around nutrients that target appetite regulation, metabolic support, and digestive balance
Patient-centered factors include comorbidities (established ASCVD or indicators of high-risk established kidney disease, or heart failure), the presence of a compelling need to minimize hypoglycemia, the need to promote weight loss or minimize weight gain, and cost [15, 17]
Alex Cook: In this study, we saw that after two years, those taking a GLP-1 drug for obesity and without diabetes, experienced an average of $4,206 higher cost of care in their second year compared to like members not taking a GLP-1 drug for obesity
Outcomes The primary outcome of the SOUL trial was time from randomization to first occurrence of MACE (a composite outcome comprising time to cardiovascular death, time to nonfatal myocardial infarction, or time to nonfatal stroke) in participants receiving oral semaglutide or placebo
Mir Ali, MD, a bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, who was not involved in the Eli Lilly study, told Healthline that while all GLP-1 drugs can work regardless of extra medical conditions, there are some unique aspects to Zepbound
As it turns out, our tongues are programmed with only one receptor that picks up on sweetness, but over 20 receptors that signal bitterness
